28426667|t|Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy
28426667|a|Degeneration and loss of lower motor neurons is the major pathological hallmark of spinal muscular atrophy (SMA), resulting from low levels of ubiquitously-expressed survival motor neuron (SMN) protein. One remarkable, yet unresolved, feature of SMA is that not all motor neurons are equally affected, with some populations displaying a robust resistance to the disease. Here, we demonstrate that selective vulnerability of distinct motor neuron pools arises from fundamental modifications to their basal molecular profiles. Comparative gene expression profiling of motor neurons innervating the extensor digitorum longus (disease-resistant), gastrocnemius (intermediate vulnerability), and tibialis anterior (vulnerable) muscles in mice revealed that disease susceptibility correlates strongly with a modified bioenergetic profile. Targeting of identified bioenergetic pathways by enhancing mitochondrial biogenesis rescued motor axon defects in SMA zebrafish. Moreover, targeting of a single bioenergetic protein, phosphoglycerate kinase 1 (Pgk1), was found to modulate motor neuron vulnerability in vivo. Knockdown of pgk1 alone was sufficient to partially mimic the SMA phenotype in wild-type zebrafish. Conversely, Pgk1 overexpression, or treatment with terazosin (an FDA -approved small molecule that binds and activates Pgk1), rescued motor axon phenotypes in SMA zebrafish. We conclude that global bioenergetics pathways can be therapeutically manipulated to ameliorate SMA motor neuron phenotypes in vivo.
28426667	0	12	Bioenergetic	T040	C0005486
28426667	13	19	status	T080	C0449438
28426667	20	29	modulates	T082	C0443264
28426667	30	42	motor neuron	T025	C0026609
28426667	43	56	vulnerability	T033	C1821973
28426667	61	73	pathogenesis	T046	C0699748
28426667	79	88	zebrafish	T013	C0043457
28426667	89	94	model	T050	C0012644
28426667	98	121	spinal muscular atrophy	T047	C0026847
28426667	122	166	Degeneration and loss of lower motor neurons	T033	C3809750
28426667	180	192	pathological	T169	C1521733
28426667	205	228	spinal muscular atrophy	T047	C0026847
28426667	230	233	SMA	T047	C0026847
28426667	288	323	survival motor neuron (SMN) protein	T116,T123	C4283935
28426667	368	371	SMA	T047	C0026847
28426667	388	401	motor neurons	T025	C0026609
28426667	414	422	affected	T169	C0392760
28426667	434	445	populations	T098	C1257890
28426667	466	491	resistance to the disease	T040	C1136180
28426667	529	542	vulnerability	T033	C1821973
28426667	555	567	motor neuron	T025	C0026609
28426667	598	611	modifications	T169	C0392747
28426667	621	645	basal molecular profiles	T169	C1704864
28426667	659	684	gene expression profiling	T059,T063	C0752248
28426667	688	701	motor neurons	T025	C0026609
28426667	718	743	extensor digitorum longus	T023	C0224464
28426667	745	762	disease-resistant	T040	C1136180
28426667	765	778	gastrocnemius	T023	C0242691
28426667	780	806	intermediate vulnerability	T033	C1821973
28426667	813	830	tibialis anterior	T023	C0242690
28426667	832	842	vulnerable	T169	C0231204
28426667	844	851	muscles	T023	C1995013
28426667	855	859	mice	T015	C0025929
28426667	860	868	revealed	T080	C0443289
28426667	874	896	disease susceptibility	T201	C0012655
28426667	933	945	bioenergetic	T040	C0005486
28426667	946	953	profile	T059	C1979963
28426667	955	964	Targeting	T169	C1521840
28426667	968	978	identified	T080	C0205396
28426667	979	991	bioenergetic	T040	C0005486
28426667	992	1000	pathways	T077	C1705987
28426667	1014	1038	mitochondrial biogenesis	T043	C3494456
28426667	1047	1057	motor axon	T026	C2335621
28426667	1058	1065	defects	T169	C0243067
28426667	1069	1072	SMA	T047	C0026847
28426667	1073	1082	zebrafish	T013	C0043457
28426667	1094	1103	targeting	T169	C1521840
28426667	1116	1128	bioenergetic	T040	C0005486
28426667	1129	1136	protein	T116,T123	C0033684
28426667	1138	1163	phosphoglycerate kinase 1	T116,T126	C3814452
28426667	1165	1169	Pgk1	T116,T126	C3814452
28426667	1185	1193	modulate	T082	C0443264
28426667	1194	1206	motor neuron	T025	C0026609
28426667	1207	1220	vulnerability	T033	C1821973
28426667	1221	1228	in vivo	T082	C1515655
28426667	1230	1239	Knockdown	T063	C2350567
28426667	1243	1247	pgk1	T028	C1418508
28426667	1258	1268	sufficient	T080	C0205410
28426667	1292	1295	SMA	T047	C0026847
28426667	1296	1305	phenotype	T032	C0031437
28426667	1309	1318	wild-type	T028	C1883559
28426667	1319	1328	zebrafish	T013	C0043457
28426667	1342	1346	Pgk1	T028	C1418508
28426667	1347	1361	overexpression	T045	C1514559
28426667	1366	1375	treatment	T061	C0087111
28426667	1381	1390	terazosin	T109,T121	C0076107
28426667	1395	1398	FDA	T170	C2700205
28426667	1409	1423	small molecule	T109	C1328819
28426667	1429	1434	binds	T052	C1145667
28426667	1439	1448	activates	T052	C1879547
28426667	1449	1453	Pgk1	T116,T126	C3814452
28426667	1464	1474	motor axon	T026	C2335621
28426667	1475	1485	phenotypes	T032	C0031437
28426667	1489	1492	SMA	T047	C0026847
28426667	1493	1502	zebrafish	T013	C0043457
28426667	1528	1541	bioenergetics	T040	C0005486
28426667	1542	1550	pathways	T077	C1705987
28426667	1558	1573	therapeutically	T169	C0302350
28426667	1600	1603	SMA	T047	C0026847
28426667	1604	1616	motor neuron	T025	C0026609
28426667	1617	1627	phenotypes	T032	C0031437
28426667	1628	1635	in vivo	T082	C1515655